Effect of Hydration Guided by Vigileo on the Prevention of CIN After Direct PCI for Patients With AMI

• Status: Not yet recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

In this study, Vigileo is used to guide hydration adjustment, and SCr is used to estimate renal function. The aim of the study is to investigate the preventive effect of adequate hydration guided by Vigileo on contrast induced nephropathy in patients with acute myocardial infarction who undergo direct PCI.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese PLA General Hospital

Criteria

Inclusion Criteria:

• Clearly diagnosed STEMI patients: ischemic chest pain lasting more than 30 minutes and adjacent 2 or more leads ST elevation (limb lead ≥0.1Mv, thoracic lead ≥0.2 mV) with or without myocardial enzymatic elevation

• Chest pain time less than 12 hours

• Patients aged 18-75 years

• Patients are scheduled to undergo direct percutaneous coronary interventions

• Estimated glomerular filtration rate eGFR <100ml / min (according to MDRD formula)

• Sign the informed consent to join the group.

Exclusion Criteria:

• Patients with mechanical complications

• Patients with cardiogenic shock who requiring IABP

• Patients with aortic dissection

• Patients who have malignant tumors or short-term progressive diseases that researchers believe improper to be included in the group

• Hemodialysis-dependent patients with end-stage renal failure

• Patients who had a history of exposure to radioactive contrast media within 1 week before or 72 hours after direct PCI

• Patients who are allergic to radioactive contrast agents

• Patients diagnosed with right ventricular myocardial infarction with hypotension (defined as systolic blood pressure ≤90 mmHg) on admission.